Supernus Pharmaceuticals SUPN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 89.4%-0.2pp | 89.6%+1.0pp | 88.6%+0.1pp | 88.5%+0.1pp | 88.4%+0.2pp | |
| Operating margin | -7.8%+0.9pp | -8.7%-3.2pp | -5.4%-15.1pp | 9.6%-1.5pp | 11.2%-1.2pp | |
| Net margin | -3.7%+1.6pp | -5.4%-2.6pp | -2.8%-12.5pp | 9.7%+0.4pp | 9.3%-1.9pp | |
| Returns | ||||||
| Return on equity | -2.8%+0.9pp | -3.7%-1.8pp | -1.9%-8.2pp | 6.4%+0.1pp | 6.3%-1.2pp | |
| Return on invested capital | -6.4%-0.1pp | -6.3%-2.5pp | -3.8%-9.1pp | 5.3%-0.1pp | 5.4%-1.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 2×+0.1× | 1.9×+0.1× | 1.8×-0.8× | 2.6×+0.1× | 2.4×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -3.9×-0.9× | -3×-0.8× | -2.3×-1.5× | -0.8×-0.2× | -0.5×-0.3× | |
| Per Share | ||||||
| Book value per share | $18.68-0.7% | $18.81+1.3% | $18.56-1.2% | $18.78+1.8% | $18.45-0.3% | |
| Valuation | ||||||
| Market capitalization | $2.98B+4.4% | $2.85B+6.3% | $2.68B+51.1% | $1.77B-3.0% | $1.83B-8.5% | |
| Price / sales | 3.8×-0.1× | 4×0.0× | 3.9×+1.3× | 2.7×-0.1× | 2.7×-0.3× | |
| Price / book | 2.8×+0.1× | 2.7×+0.1× | 2.6×+0.9× | 1.7×-0.1× | 1.8×-0.2× | |
| EV / EBITDA | 76.6×-17.7× | 94.3×+41.3× | 53×+41.6× | 11.5×+0.2× | 11.3×-0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Supernus Pharmaceuticals's profit margins?
- Supernus Pharmaceuticals (SUPN) runs a 89.4% gross margin and a -7.8% operating margin, with a -3.7% net margin.
- Where do Supernus Pharmaceuticals's ratios come from?
- Every ratio is computed from Supernus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
